The Hedgehog Pathway Inhibitors Market is expected to grow between 2025 and 2032, driven by the increasing prevalence of basal cell carcinoma and other hedgehog-driven cancers and the approval of second-generation inhibitors. Advances in combination regimens, trial-stage assets, and expanding indications fuel market evolution in oncology-targeted therapy. https://www.datamintelligence.com/research-report/hedgehog-pathway-inhibitors-market